Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.

@article{Njoroge2008ChallengesIM,
  title={Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.},
  author={F. George Njoroge and Kevin X. Chen and Nengyang Shih and John J. Piwinski},
  journal={Accounts of chemical research},
  year={2008},
  volume={41 1},
  pages={
          50-9
        }
}
More than 170 million people worldwide are affected by the hepatitis C virus (HCV). The disease has been described as a "silent epidemic" and "a serious global health crisis". HCV infection is a leading cause of chronic liver disease such as cirrhosis, carcinoma, or liver failure. The current pegylated interferon and ribavirin combination therapy is effective in only 50% of patients. Its moderate efficacy and apparent side effects underscore the need for safer and more effective treatments. The… 
Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.
TLDR
Unique features of the HCV helicase, recently discovered compounds that inhibit HCV Helicase catalyzed reactions and HCV cellular replication, and new methods to monitor helicase action in a high-throughput format are discussed.
Development of boceprevir: a first‐in‐class direct antiviral treatment for chronic hepatitis C infection
TLDR
The discovery and development of a first‐in‐class direct antiviral treatment for chronic hepatitis C infection, boceprevir, marketed around the world as VictrelisTM is described.
Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
  • Y. Tsantrizos
  • Biology, Chemistry
    Accounts of chemical research
  • 2008
TLDR
The progress made toward overcoming the stigma of poor drug-like properties, low oral absorption, and high clearance associated with such compounds is summarized and the drug discovery efforts that have focused specifically on human immunodeficiency virus (HIV) and hepatitis C virus (HCV) protease inhibitors are highlighted.
Safety of small molecules in combination with interferon-based therapy for hepatitis C virus
  • V. Rustgi
  • Medicine
    Expert opinion on drug safety
  • 2010
TLDR
The central questions to successful multidrug combination therapies including novel small molecules will be their composite safety and efficacy profiles.
Gene therapies for hepatitis C virus.
TLDR
A comprehensive overview guides you through the current developments and applications of RNAi and microRNA-based gene therapy strategies in HCV treatment, including newly developed gene therapy regimens provided to treat HCV.
Zika Virus Protease: An Antiviral Drug Target.
Resistance mutations against HCV protease inhibitors and antiviral drug design.
TLDR
This review summarizes the mutations that are responsible for resistance against the two approved protease inhibitors and several compounds in advanced clinical trials that are used clinically in combination with direct acting antivirals (DAAs).
New Drug Review Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C
TLDR
Boceprevir was well tolerated in clinical trials and a welcomed addition to the HCV armamentarium.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
TLDR
Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor, illustrating the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
TLDR
The overall preclinical profile of VX-950 supports its candidacy as a novel oral therapy against hepatitis C and a recently developed HCV protease mouse model showed excellent inhibition of HCV NS3-4A protease activity in the liver.
Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
TLDR
The strategy of macrocyclization from the P2 proline to P3 capping to enhance binding to the backbone Ala156 residue and the S4 pocket has been successful in improving potency and in structural depeptization.
Hepatitis C: progress and problems.
  • J. Cuthbert
  • Medicine, Biology
    Clinical Microbiology Reviews
  • 1994
TLDR
Prevention of HCV infection by vaccination is likely to be challenging if ongoing viral mutation results in escape from neutralization and clearance.
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
TLDR
Findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively.
Challenges and successes in developing new therapies for hepatitis C
TLDR
Preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs, and combinations of multiple agents will be required to treat chronic HCV infection.
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
TLDR
A better understanding of the mechanism of action of IFN and ribavirin will be essential to optimize current therapeutic strategies and to develop new therapies.
The Scientific Challenge of Hepatitis C
TLDR
Although to date no one has been able to grow HCV reliably in a laboratory culture of cells, on page 110, researchers describe a new system for culturing HCV9s RNA.
Course and outcome of hepatitis C
TLDR
The hepatitis C virus is a small enveloped RNA virus belonging to the family flaviviridae and genus hepacivirus that replicates at a high rate in the liver and has marked sequence heterogeneity.
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.
TLDR
The view is concluded that severe, life-threatening, progressive liver disease clearly occurs in a sizable minority of chronically infected persons but it is speculated that fibrosis progression is neither linear or inevitable and hence that most hepatitis C virus carriers will have either a stable nonprogressive course or such indolent progression that they will die from an unrelated disease before the severe sequelae of hepatitis C become manifest.
...
1
2
3
4
5
...